Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.64 |
| ▸ | TNF | P01375 | 6/20 | 0.64 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926852 | 0.86 | MCHR1 (0.56) | NOD1TNFNOD2HTR2CMCHR1 | |
| SCHEMBL2925651 | 0.85 | MCHR1 (0.81) | HTR2CMCHR1SMN1; SMN2KDM4E | |
| SCHEMBL2927193 | 0.84 | MCHR1 (0.68) | HTR2CMCHR1SMN1; SMN2LMNATSHR | |
| SCHEMBL2925096 | 0.84 | MCHR1 (0.80) | HTR2CMCHR1SMN1; SMN2KDM4E | |
| SCHEMBL2925711 | 0.83 | MCHR1 (0.64) | HTR2CMCHR1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2926277 | 0.83 | MCHR1 (0.56) | TNFHTR2CMCHR1MEN1KMT2A | |
| SCHEMBL2920492 | 0.83 | MCHR1 (0.68) | HTR2CMCHR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13177290 | 0.82 | MCHR1 (0.62) | HTR2CMCHR1LMNA | |
| SCHEMBL2926399 | 0.81 | MCHR1 (0.64) | HTR2CMCHR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2920455 | 0.80 | MCHR1 (0.65) | HTR2CMCHR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-1285651-B1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-6930185-B2 | Melanin-concentrating hormone antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1285651-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077628-A1 | Melanin-concentrating hormone antagonist | MCHR1, MC1R, MCHR2 | NOD1 695/4885TNF 3581/4885NOD2 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.